EGFR and non-small cell lung carcinoma: The proteomic approach, which included a gel-based [65], antibody-based [66], and MS-based technique [67], was performed to analyze biofluid samples from NSCLC patients who responded differently to EGFR-TKI as summarized in (Table 3).